My only point was if there are forces that are against leronlimab being approved for any indication (not yet proven), and if those forces have influence within the FDA (again, not yet proven), then the confidential back-channel that exists between the US FDA and the UK MHRA could potentially be used to delay or undermine our approvals in the UK.

As to what exactly could be said to "poison the UK decision" -- I think there's no limit as to what could be said to achieve that goal.

Source Link: https://www.fda.gov/international-programs/co...commitment